You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨創新藥概念股強勢 再鼎醫藥大升超10% 恒瑞醫藥升超3%
港股創新藥概念股普遍強勢,其中,信達生物大升16%,再鼎醫藥大升超10%,諾誠健華升超5%,中國生物製藥、石藥集團、復星醫藥升超4%,百濟神州、先聲藥業、恒瑞醫藥升超3%。消息面上,儘管關税談判多變,5月至少6家國內創新藥企對外官宣了BD交易訂單,證明對關税對創新藥企的全球化影響可控。日前醫藥巨頭百時美施貴寶宣佈與德國生物技術公司BioNTech就新一代抗癌藥物BNT327達成授權協議,交易價值可高達111億美元。此外,今年的AACR和ASCO兩項會議體現中國創新藥在新靶點、新技術、新疾病領域的領先趨勢。有機構認為,創新藥產業已經歷4年下行,前期預期過度悲觀,目前政策轉向需求迫切,趨勢已確立,空間較大。(格隆匯)

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account